Cerus Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERS research report →
Companywww.cerus.com
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
- CEO
- William Greenman
- IPO
- 1997
- Employees
- 614
- HQ
- Concord, CA, US
Price Chart
Valuation
- Market Cap
- $538.99M
- P/E
- -54.69
- P/S
- 2.42
- P/B
- 7.73
- EV/EBITDA
- -42.07
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.31%
- Op Margin
- -7.94%
- Net Margin
- -4.29%
- ROE
- -15.36%
- ROIC
- -10.34%
Growth & Income
- Revenue
- $206.13M · 14.35%
- Net Income
- $-15,627,000 · 25.29%
- EPS
- $-0.08 · 25.45%
- Op Income
- $-36,346,000
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $3.15
- 52W Low
- $1.15
- 50D MA
- $2.06
- 200D MA
- $1.86
- Beta
- 1.63
- Avg Volume
- 2.24M
Get TickerSpark's AI analysis on CERS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 1, 26 | Jayaraman Vivek K | sell | 16,667 |
| Apr 1, 26 | Green Kevin Dennis | other | 200,000 |
| Apr 1, 26 | Jensen Chrystal | other | 200,000 |
| Mar 12, 25 | Jensen Chrystal | sell | 113,008 |
| Mar 12, 26 | Jayaraman Vivek K | sell | 165,200 |
| Mar 12, 26 | Greenman William Mariner | sell | 447,757 |
| Mar 12, 26 | Green Kevin Dennis | sell | 127,544 |
| Mar 12, 26 | Benjamin Richard J | sell | 101,740 |
| Mar 5, 26 | Benjamin Richard J | sell | 61,233 |
| Mar 5, 26 | Green Kevin Dennis | other | 63,854 |
Our CERS Coverage
We haven't published any research on CERS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CERS Report →